Contribute to cutting edge gene therapy
Support BioViva’s new dementia study:
Help us meet our $2 million target
The Coalition for Radical Life Extension, a Not-for-Profit 501 (C)(3), is raising money to fund a new study with BioViva. This ethics board approved safety study with efficacy will involve 10 patients and be conducted in Mexico. Cost is approximately $200,000 per patient.
This sponsored, interventional, non-randomized study without a control group will use a novel and proprietary central nervous system gene transfer method to deliver AAV hTert and Klotho genes to patients with mild or moderate dementia, with suspected Alzheimer’s disease.
Inclusion:
50 years of age or above.
Diagnosis of mild to mid stage dementia, with suspected Alzheimer's disease.
Current bloodwork and functional MRI imaging required.
Exclusion:
Active cancer
Psychosis
Liver disease
Pregnancy
As determined by treating physician
This study builds on a preliminary study which found after a one year follow up that all five patients demonstrated evident reversal of Dementia symptoms, such as sustained cognitive improvement as measured by the Folstein exam. Telomere analysis was performed before and after the therapy. A measurable elongation of the participants telomeres was identified, and biological age, in regards to telomere length, was reduced as chronological age increased.
